K-Medtechs accelerate North America expansion

Expansion of clinical data–driven research results… highlights reliability of K-AI

Platform and efficiency-focused technology competition... Adoption in North America accelerates

Innovation in ultrasound and X-ray–based devices strengthens K-Medtech’s presence

RSNA2025 site (RSNA Webpage)

At this year’s Radiological Society of North America Annual Meeting (RSNA 2025), Korean medical device and AI companies fully unveiled their research achievements and platform capabilities, outlining concrete strategies for global market expansion.

In particular, solutions addressing real-world issues in radiology workflows—such as interpretation discrepancies, diagnostic errors, and data bottlenecks—have increased, clearly shifting the focus toward clinical value.

K-AI accelerates efforts to secure trust in the North American market with clinical data
RSNA 2025, the world's largest event gathering of radiologists and global healthcare companies, is being held in Chicago, USA, from November 30 to December 4.

Marking its 111th year, this year's event, themed ‘Imaging the Individual’ (advancements in medical imaging technology for personalized diagnosis and treatment), showcases the latest trends in AI-based radiology devices, medical imaging equipment, and software.

While RSNA has traditionally been a platform for global conglomerates to showcase hardware-centric technological prowess, Korean companies, particularly AI firms, are increasingly leveraging the event as a stage to demonstrate both technological capabilities and clinical reliability.

First, Lunit, a leader in the AI field, clearly established its presence as one of the companies that secured the most research presentations, including 14 research abstracts. Notably, 8 of these abstracts were oral presentations, placing Lunit’s achievements in the upper tier even by North American academic standards.

The oral presentations included studies on shifting the breast cancer screening paradigm from AI-supported double reading to AI-supported single reading, as well as research on how changes in breast density affect calibration of risk-prediction models.

(Clockwise from top left) Deepnoid, Lunit, Crescom, Heuron – RSNA 2025 participant overview

Lunit, operating its first integrated booth with Lunit International (formerly Volpara) since brand integration, plans to showcase its full-cycle AI solutions—from cancer diagnosis to risk prediction—based on this academic credibility, accelerating its expansion into the North American market.

Deepnoid introduced 5 research abstracts focused on AI reliability, interpretability, and reproducibility, including addressing performance gaps in chest X-rays and error detection using vision-language models. It also plans to concentrate on sharing academic achievements and laying the groundwork for global market entry through its exhibition booth.

Heuron presented solutions for diagnosing acute stroke and degenerative brain diseases, along with research achievements based on vascular-imaging CT. Musculoskeletal AI specialist Crescom showcased MediAI-BA, a bone-age assessment solution using hand X-ray, and its MediAI-OA quantitative knee osteoarthritis analysis solution, targeting the musculoskeletal-specific market

‘Real-world use-focused’ strategy…Trend shifts toward platform and workflow efficiency enhancement
While some companies demonstrated technological prowess through research achievements, others focused on resolving bottlenecks in clinical workflows within their specialized domains.

Coreline Soft exemplified this approach by demonstrating its advanced chest AI platform, AVIEW 2.0, emphasizing its integrated workflow and improved efficiency.

Coreline Soft AVIEW 2.0

AVIEW 2.0 is designed so that interpretation, reporting, and explanation occur seamlessly within a single interface, offering a practical solution that drastically reduces communication steps that typically consume significant clinical time.

Building on these achievements, major US medical institutions like UMass Memorial Medical Center have begun adopting AVIEW in routine radiology workflows, contributing to demonstrating the company’s tangible progress in the North American market.

Additionally, MaiHub, Korea's first integrated medical AI platform company, made its debut at this year's RSNA to showcase its AI solution integration strategy.

MaiHub emphasized a differentiated strategy centered on its medical AI integration platform maiLink, and the patient-facing AI analysis report app, maiReport. This strategy involves providing various AI solutions integrated on a single platform and delivering personalized patient reports.

The company particularly emphasized its package-based AI-solution offerings designed to enhance partner companies’ market access and reduce the burden of AI adoption for clinicians. MaiHub is currently preparing for U.S. FDA 510(k) clearance next year, fueling expectations for the expansion of global partnerships. 

Samsung Medison focuses on securing ‘diagnostic consistency,’ increases presence

While AI companies showcased capabilities centered on software technology, Samsung Medison is targeting the market with next-generation imaging solutions that enhance the accuracy and consistency of diagnostic imaging.

Samsung Medison unveiled R20, its first premium ultrasound diagnostic device dedicated to radiology, in the US market, and emphasized its high-resolution technology.

The core technology of the R20 is 3rd-harmonic–based image processing. By using frequencies three times higher than the base signal, it delivers clear and stable images regardless of a patient’s body type, age, or sex, thereby reducing interpretation variability between examiners.

(From left) Samsung Medison, Heuron’s RSNA 2025 booths

It also incorporates deep learning-based real-time AI assistance designed to detect and visualize areas of interest in real time.

Samsung additionally showcased a different approach focused on patient safety and operational efficiency. Alongside low-dose X-ray technology, the company introduced features aimed at reducing retake rates.

Kyu Tae Yoo, GM & Global Head of Healthcare Business at Samsung Electronics and CEO of Samsung Medison, said, “Samsung is concentrating its technological capabilities on solving challenges raised in clinical settings, such as image-quality variation tied to patient characteristics. By advancing AI features and low-dose technology, we aim to enhance diagnostic efficiency and patient safety simultaneously, establishing a new standard in the medical imaging market.”

Global leaders demonstrate strength… GE and Canon unveil new technologies
Meanwhile, global companies also showcased new technologies at RSNA 2025, maintaining the broader trends of imaging precision, operational efficiency, and data-driven diagnostics.

Canon Medical Systems attracted attention with the world’s first multi-position CT, designed to meet practical, real diagnostic needs at the point of care.

Overcoming the limitation of conventional CTs requiring patients to lie down for imaging, this equipment enables scans while patients are standing or seated in a special chair. This is expected to help identify causes previously detectable only under weight-bearing posture and contribute to the early detection of physical function decline in super-ageing populations.

Yoo Eegeun, Head of Canon Medical Systems Korea’s CT Division, said, “With the introduction of the world’s first multi-position CT at RSNA this year, Canon Medical is presenting a new paradigm with a truly innovative technology that addresses practical needs in the medical field. We will strive to bring this innovation to the domestic market as quickly as possible.”

(From left) GE Healthcare RSNA 2025 booth, Canon Medical Systems Multi-Position CT

GE Healthcare, building on its symbolic history of 111 consecutive participations since RSNA's inaugural event in 1914, specifically unveiled the outcomes of its R&D investments exceeding USD 3 billion since 2022.

Specifically, the company unveiled “Photonova Spectra,” a next-generation photon-counting CT (PCCT) system, and “SIGNA Sprint,” an advancement within its next-generation SIGNA MRI line.

GE Healthcare CEO Peter Arduini said, “Our mission in shaping the future of healthcare is clear: to provide innovative technologies that support clinicians, enhance operational efficiency, and improve patient outcomes.”